Claim OwnershipThe Lens: Life Sciences Reinvention in Focus
Subscribed: 10Played: 89
Subscribe
© 2021 Accenture. All rights reserved.
Description
Tune in to industry innovators sharing real experiences – turning digital potential into a competitive advantage and improving patient outcomes. Previously known as Driving Digital in Biopharma.
36 Episodes
Reverse
In this episode, Tom Lehmann talks with Natasha Kelly, a data scientist within Accenture's Applied Intelligence Group who focuses on advanced analytic solutions in life sciences manufacturing and supply chain. Tom and Natasha discuss the 2022 Life Sciences Technology Vision through a supply chain lens, delving into how each of the report's four trends ingrained in the metaverse are reshaping supply chain and operations experiences across the industry.
In this episode, host Tom Lehmann speaks with Sanjay Patel, Global Head of Innovation Capability Solutions & Services at Takeda, regarding how global collaboration and innovative leadership are reshaping the biotech landscape. Sanjay shares insights into the five-hub network he’s building to strengthen Takeda’s data, AI, and product-engineering capabilities through Innovation Capability Centers (ICCs). He discusses the impact of AI and emerging technologies, including Takeda’s internal GenAI assistant “MyAibou,” and how thoughtfully designed workspaces are helping overcome return-to-office fatigue. Tune in for candid lessons on scaling innovation, breaking silos, and keeping curiosity at the core—plus how patient-centered solutions like the “For You, With You: IBD” app are changing lives.
Discover how digital innovation and Gen AI are reshaping pharma with Anvita Karara. Explore how patient-centricity, personalization, and responsible AI are driving better health outcomes and transforming engagement at scale.
An episode with Tracy Ring, Accenture’s Chief Data Officer and Global Generative AI Lead for Life Sciences explores how advanced AI, cognitive digital brains, and agentic systems are transforming business efficiency, trust, and customer interactions.
A discussion with David Hole, Global Life Sciences T&O lead about how GenAI is transforming the life sciences workforce, emphasizing the need for new skills, ethical considerations, and the balance between democratization and governance.
Matt Studney, from Merck’s Research Laboratories Information Technology discusses AI's growing role in pharma and the need for responsible implementation to enhance health outcomes.
Explore how Genentech’s digital cell and gene therapy innovation scales life-saving treatments. From virtual journeys to secure supply chains, learn about the tech and collaborations bringing new therapies safely to patients worldwide.
In this insightful episode of Driving Digital in Biopharma, host Tom Lehmann explores with Áine Hanly, Chief Technology Officer at Vir Biotechnology, the transformative role of data and technology in drug development and manufacturing. Áine delves into the advancements in data accessibility and automation, such as single-cell manipulation and high throughput processes, which have notably shortened cycle times and boosted efficiency. She also discusses the innovative use of the Vir AI tool Daisy for antibody design and optimization, which speeds up the process and enhances manufacturability. The episode wraps up by highlighting the critical importance of a robust data strategy and the power of cross-functional partnerships in fostering innovation and operational efficiency across the biopharma industry.
This episode of Driving Digital in Biopharma offers a peek into the digital revolution brewing in the biopharma labs, courtesy of Richard Milne, the Vice-president and general manager of Digital Science Solutions at Thermo Fisher Scientific. From e-commerce roots to pioneering digital science, Richard and Tom delve into the vision for laboratories, and the integration of artificial intelligence and automation in scientific research and lab operations. Their conversation highlights the critical role of digital strategies in enhancing productivity and accelerating scientific advancements. Richard also gives his insights on the future potential of automation and robotics in laboratories, alongside the challenges and opportunities that AI presents in revolutionizing the drug discovery process.
In this episode of "Driving Digital in Biopharma," host Tom Lehmann welcomes Morrey Atkinson, the Chief Technology and Operations Officer at Vertex Pharmaceuticals. With a rich background in process development and manufacturing within the pharmaceutical industry, Morrey shares his insights on Vertex's strategic evolution and its commitment to serial innovation through substantial investments in R&D. They discuss the company’s modality-agnostic approach, which allows flexibility in tackling various diseases, as well as covering the strategic use of contract development and manufacturing organizations (CDMOs) to optimize Vertex's global manufacturing footprint, ensuring rapid and reliable delivery of therapies to patients worldwide. Listeners will gain a comprehensive understanding of how Vertex Pharmaceuticals leverages digital innovation to maintain its leadership in drug development and manufacturing, setting new standards in the biopharma industry.
In this episode of Driving Digital in Biopharma, Accenture host, Tom Lehmann, speaks to Chris Braithwaite, Global Head of Drug Development, Digital and IT Novartis. Achieving digital transformation requires a delicate balance between traditional methods, rapidly emerging technology, and human decision-making. Chris encourages a shift in perspective and a focus on change management, emphasizing that working in a human+machine mode does not entail eliminating human roles. Instead, it involves developing comfort and knowledge regarding data and technology to enhance human potential and increase role effectiveness. By embracing digital tools and leveraging data, organizations can empower themselves to make informed decisions, drive adoption, and ultimately improve patient care.
In this episode of Driving Digital in Biopharma, Accenture host, Tom Lehmann, talks with Michel Rider, VP Digital, Analytics and Performance at GSK. Michel reflects on their multi-year quest to modernize digital, data, and analytics capabilities across Development – sharing insights for achieving near-term wins while planning for the future. There is a sense of urgency for patients seeking better, faster treatments. And this is a non-linear endeavor – iteration and evolution are a given. A compressed transformation approach combined with agile experimentation can deliver tangible benefits quickly and establish a foundation for future growth.
In this episode of Driving Digital in Biopharma, host Tom Lehmann talks with Jason Bronfeld, Head of Product Development IT at Bristol-Myers Squibb, about the industry re-perceiving itself and capitalizing on the power of digital. When it comes to evolving ways of operating to an ever-better model for the future, a mindset shift is essential – digital is a means and not the end. The biopharma industry is viewed as knowledge-generating enterprises, and while ever-growing amounts of data present complex challenges, a strong digital core will fuel competitive advantages.
In this episode, Tom Lehmann talks with Accenture’s Ross Wooddisse, Managing Director and Life Sciences R&D Lead in Europe, about the 2022 Life Sciences Technology Vision and what the Metaverse continuum means for Biopharma R&D. They discuss how science turns into medicine, a new generation of digital trial capabilities and the fundamental opportunity for the industry to move from disease management towards risk prediction and disease prevention.
In this episode Tom Lehmann talks with Shalu Chada, Managing Director and Accenture’s Life Sciences Technology Lead, to discuss the 2022 Life Sciences Technology Vision and how each of the report's four trends ingrained in the metaverse are reshaping biopharma experiences of the future.
In this episode of Driving Digital in Biopharma, host Tom Lehmann talks with Anders Persson – Executive Director, Ecosystem Strategy & Innovation, AstraZeneca, about the role of digital and data in the transformation of global drug development and the value of an ecosystem and partnership strategy in R&D.
Tom Lehmann and Eddie Reilly, Chief regulatory officer and head of global regulatory affairs, Sanofi discuss delivering new therapies to patients more efficiently and how that’s enabled by regulatory affairs - from standardizing data and harnessing AI to the more proficiently exchanging data with health authorities.
Host Tom Lehmann talks with Lars Fogh Iversen, Senior Vice Present for Digital Science & Innovation at Novo Nordisk. They discuss the journey to accelerate research and early development through laboratory automation, data management, AI and digital research.
In Episode 11, host Tom Lehmann and guest Julie Huxley-Jones, GSK, discuss the mindset of scientific curiosity, innovation and collaboration and its role on the impact of digital in scientific discovery. They talk about the unique journey of digital in discovery research and how it’s increasing productivity and innovation.
Savyon Amit talks with Tom Lehmann about AstraZeneca's aligned understanding of Digital Health and the importance of articulating the value of digital from an organizational standpoint as well as value to the broader healthcare ecosystem.
Comments
Download from Google Play
Download from App Store
United States